Idioma:

Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial

Howells, Lynne M ; Iwuji, Chinenye O O ; Irving, Glen R B ; Barber, Shaun ; Walter, Harriet ; Sidat, Zahirah ; Griffin-Teall, Nicola ; Singh, Rajinder ; Foreman, Nalini ; Patel, Samita R ; Morgan, Bruno ; Steward, William P ; Gescher, Andreas ; Thomas, Anne L ; Brown, Karen

The Journal of nutrition, 2019-07, Vol.149 (7), p.1133-1139 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial
Autor: Howells, Lynne M ; Iwuji, Chinenye O O ; Irving, Glen R B ; Barber, Shaun ; Walter, Harriet ; Sidat, Zahirah ; Griffin-Teall, Nicola ; Singh, Rajinder ; Foreman, Nalini ; Patel, Samita R ; Morgan, Bruno ; Steward, William P ; Gescher, Andreas ; Thomas, Anne L ; Brown, Karen
Assuntos: 5-Fluorouracil ; Administration, Oral ; Aged ; Anticancer properties ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer ; Chemical compounds ; Chemotherapy ; Clinical trials ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - pathology ; Curcumin ; Curcumin - administration & dosage ; Curcumin - therapeutic use ; curcuminoids ; Enzyme-linked immunosorbent assay ; Evidence-based medicine ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - therapeutic use ; FOLFOX chemotherapy ; Folinic acid ; Humans ; Ionization ; Leucovorin - administration & dosage ; Leucovorin - therapeutic use ; Liquid chromatography ; Male ; Mass spectrometry ; Mass spectroscopy ; Metastases ; metastatic colorectal cancer ; Middle Aged ; Motivation ; Neoplasm Metastasis ; Neurotoxicity ; Organoplatinum Compounds - administration & dosage ; Organoplatinum Compounds - therapeutic use ; Original ; Oxaliplatin ; Quality assessment ; Quality of life ; Questionnaires ; Randomization ; randomized controlled trial ; Safety ; Survival ; Toxicity ; Treatment Outcome
É parte de: The Journal of nutrition, 2019-07, Vol.149 (7), p.1133-1139
Notas: LMH and COOI contributed equally to this work.
Descrição: Curcumin is the main active ingredient of the spice turmeric, investigated extensively for putative anticancer properties. This phase IIa open-labelled randomized controlled trial aimed to assess safety, efficacy, quality of life, neurotoxicity, curcuminoids, and C-X-C-motif chemokine ligand 1 (CXCL1) in patients receiving folinic acid/5-fluorouracil/oxaliplatin chemotherapy (FOLFOX) compared with FOLFOX + 2 g oral curcumin/d (CUFOX). Twenty-eight patients aged >18 y with a histological diagnosis of metastatic colorectal cancer were randomly assigned (1:2) to receive either FOLFOX or CUFOX. Safety was assessed by Common Toxicity Criteria-Adverse Event reporting, and efficacy via progression-free survival (PFS) and overall survival (OS). Quality of life and neurotoxicity were assessed using questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and Functional Assessment of Cancer Treatment-Gynecologic Oncology Group-Neurotoxicity). Plasma curcuminoids were determined with liquid chromatography (LC) electrospray ionization tandem mass spectrometry and CXCL1 by ELISA. Addition of daily oral curcumin to FOLFOX chemotherapy was safe and tolerable (primary outcome). Similar adverse event profiles were observed for both arms. In the intention-to-treat population, the HR for PFS was 0.57 (95% CI: 0.24, 1.36; P = 0.2) (median of 171 and 291 d for FOLFOX and CUFOX, respectively) and for OS was 0.34 (95% CI: 0.14, 0.82; P = 0.02) (median of 200 and 502 d for FOLFOX and CUFOX, respectively). There was no significant difference between arms for quality of life (P = 0.248) or neurotoxicity (P = 0.223). Curcumin glucuronide was detectable at concentrations >1.00 pmol/mL in 15 of 18 patients receiving CUFOX. Curcumin did not significantly alter CXCL1 over time (P = 0.712). Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer. This trial was registered at clinicaltrials.gov as NCT01490996 and at www.clinicaltrialsregister.eu as EudraCT 2011-002289-19.
Editor: United States: Elsevier Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial

Howells, Lynne M ; Iwuji, Chinenye O O ; Irving, Glen R B ; Barber, Shaun ; Walter, Harriet ; Sidat, Zahirah ; Griffin-Teall, Nicola ; Singh, Rajinder ; Foreman, Nalini ; Patel, Samita R ; Morgan, Bruno ; Steward, William P ; Gescher, Andreas ; Thomas, Anne L ; Brown, Karen

United States: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.